Semler Scientific (NASDAQ:SMLR) Upgraded at Maxim Group

Semler Scientific (NASDAQ:SMLR - Get Free Report) was upgraded by stock analysts at Maxim Group to a "strong-buy" rating in a report released on Wednesday, MarketBeat Ratings reports. The brokerage presently has a $95.00 price target on the stock. Maxim Group's price objective would indicate a potential upside of 108.65% from the company's previous close.

Other equities analysts have also recently issued research reports about the stock. Benchmark began coverage on shares of Semler Scientific in a research note on Tuesday. They set a "buy" rating and a $101.00 target price on the stock. Wall Street Zen cut shares of Semler Scientific from a "buy" rating to a "sell" rating in a research note on Thursday, May 22nd.

Semler Scientific Stock Performance

SMLR stock traded down $0.44 during mid-day trading on Wednesday, reaching $45.53. The company had a trading volume of 1,187,049 shares, compared to its average volume of 570,088. The company has a quick ratio of 0.51, a current ratio of 0.52 and a debt-to-equity ratio of 0.59. Semler Scientific has a one year low of $21.77 and a one year high of $81.56. The stock's 50-day simple moving average is $37.47 and its two-hundred day simple moving average is $42.06. The stock has a market capitalization of $623.31 million, a P/E ratio of -17.44 and a beta of 1.39.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.76) earnings per share for the quarter. Semler Scientific had a positive return on equity of 19.75% and a negative net margin of 60.69%. The firm had revenue of $8.84 million during the quarter.

Hedge Funds Weigh In On Semler Scientific

Several large investors have recently made changes to their positions in SMLR. Interchange Capital Partners LLC bought a new position in shares of Semler Scientific during the 1st quarter valued at about $46,502,000. Capital International Investors bought a new position in shares of Semler Scientific during the 4th quarter valued at about $30,813,000. Susquehanna Advisors Group Inc. bought a new position in shares of Semler Scientific during the 4th quarter valued at about $26,928,000. Driehaus Capital Management LLC bought a new position in shares of Semler Scientific during the 4th quarter valued at about $10,122,000. Finally, Thames Capital Management LLC bought a new position in shares of Semler Scientific during the 4th quarter valued at about $6,465,000. Institutional investors own 49.37% of the company's stock.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.